【TLC Biosciences Corp.】Q1 2026 EPS -0.10 NTD
NQ Score
0/100
N1 Content Completeness
4
AI Summary (NQ-processed)
TLC Biosciences Corp. reported its Q1 2026 financial results with an EPS of -0.10 NTD, operating revenue of 0.45 billion NTD, and net income after tax of -0.15 billion NTD. The company is navigating the financial challenges typical of the biotechnology and medical industry's R&D phase.